alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 326–350 of 963 studies with an author at Harvard University (US) (page 14 of 39) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Circulating cortisol and cognitive and structural brain measures: The Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2018-10-24

We evaluated dementia-free Framingham Heart Study (generation 3) participants (mean age 48.5 years, 46.8% men) who underwent cognitive testing for memory, abstract reasoning, visual perception, attention, and executive function (n = 2,231) and brain MRI (n = 2018) to assess total white matter, lobar gray matter, and white matter hyperintensity volumes and fractional anisotropy (FA) measures. 4 key findings →

Participants: 2,231 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Sleep, physical activity, sedentary behavior, and risk of incident dementia: a prospective cohort study of 431,924 UK Biobank participants

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Molecular psychiatry 2022-06-14

Although sleep, physical activity and sedentary behavior have been found to be associated with dementia risk, findings are inconsistent and their joint relationship remains unclear. 4 key findings →

Participants: 431,924 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Loneliness, Not Social Support, Is Associated with Cognitive Decline and Dementia Across Two Longitudinal Population-Based Cohorts

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of Alzheimer's disease : JAD 2022-01-01

Poor social health is likely associated with cognitive decline and risk of dementia; however, studies show inconsistent results. 4 key findings →

Participants: 4,514 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Science (New York, N.Y.) 2023-03-16

Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Social exposome and brain health outcomes of dementia across Latin America

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Nature Communications 2025-09-11

A multidimensional social exposome (MSE)-the combined lifespan measures of education, food insecurity, financial status, access to healthcare, childhood experiences, and more-may shape dementia risk and brain health over the lifespan, particularly in underserved regions like Latin America. 1 key finding →

Participants: 2,211 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Emergency Department Hallways Are Associated With Incident Delirium and Severe Agitation in Older Adults Living With Dementia

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of the American Geriatrics Society 2026-01-16

Our sample included 11,105 patients (median age 77, 51% female), with 2299 in the hallway group and 8806 in the non-hallway group. 5 key findings →

Design: retrospective cohort Participants: 11,105 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Markers of Left Atrial Myopathy: Prognostic Usefulness for Ischemic Stroke and Dementia in People in Sinus Rhythm

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Stroke 2025-03-07

Among 4712 participants (59% female; mean age, 74 years), 193 ischemic strokes and 769 dementia cases were ascertained over a median follow-up of 8.3 years. 5 key findings →

Design: cohort study Participants: 4,712 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer s & Dementia 2014-05-02

There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer s & Dementia 2022-07-31

Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials.

Full summary, score breakdown and related studies → Original source Free full text

Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Annals of neurology 2000-04-01

We used magnetic resonance imaging (MRI) measurements to determine whether persons in the prodromal phase of Alzheimer's disease (AD) could be accurately identified before they developed clinically diagnosed dementia. 1 key finding →

Participants: 24 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Quality of End-of-Life Care Provided to Patients With Different Serious Illnesses

✓ Peer-reviewed alzhub usefulness score 59 out of 100. JAMA internal medicine 2016-08-01

Among 57 753 decedents, approximately half of the patients with ESRD, cardiopulmonary failure, or frailty received palliative care consultations (adjusted proportions, 50.4%, 46.7%, and 43.7%, respectively) vs 73.5% of patients with cancer and 61.4% of patients with dementia (P Conclusions and relevance Family-reported quality of end-of-life care was significantly better for patients with cancer and those with dementia than for patients with ESRD, cardiopulmonary failure, or frailty, largely owing to higher rates of palliative care consultation and do-not-resuscitate orders and fewer deaths in the intensive care unit among patients with cancer and those with dementia. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Delirium symptoms in post-acute care: prevalent, persistent, and associated with poor functional recovery

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of the American Geriatrics Society 2003-01-01

The data from this study provide strong preliminary evidence that, in patients newly admitted to post-acute care facilities from acute care hospitals, delirium symptoms are prevalent, persistent, and associated with poor functional recovery. 4 key findings →

Design: cohort study Participants: 551 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's research & therapy 2024-01-02

DCR outperforms the MMSE in detecting and classifying cognitive impairment-in a fraction of the time-while being not influenced by a patient's ethnicity. 5 key findings →

Participants: 360 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Changes in Everyday and Digital Health Technology Use Among Seniors in Declining Health

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2018-03-01

Between 2011 and 2014, seniors experiencing health decline used various digital health technologies at low absolute rates (range: 1%-20%). 2 key findings →

Design: longitudinal study Participants: 4,037 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed